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ABSTRACT  1 
 2 
Background: Mutations of the AIP gene have been reported to occur in 15-40% of patients with familial 3 
isolated pituitary adenoma (FIPA). In addition to missense, nonsense and small insertion/deletion 4 
mutations, large gene deletions and mutations affecting possible splice-sites or promoter regions have also 5 
been described. 6 
 7 
Aims: To study AIP sequence changes in a large cohort of FIPA families and functionally characterize 7 8 
germline AIP changes, some of which do not change the amino-acid sequence.  9 
 10 
Methods: FIPA kindreds were studied for AIP mutations using sequencing and multiple ligation-11 
dependent probe amplification (MLPA). An in vitro luciferase assay was used to study promoter activity 12 
and regulation, while patient blood RNA and minigene constructs were utilized to study splicing 13 
abnormalities. Yeast two-hybrid assay was used to study AIP-phosphodiesterase-4A5 protein interaction. 14 
 15 
Results: Of 64 FIPA families, 20 demonstrated AIP mutations, including 3 families with large deletions. 16 
Luciferase-assay studies of a dibasic promoter mutation showed reduced basal promoter activity. 17 
Furthermore, stimulation of GH3 cells with forskolin, db-cAMP and phorbol-12-myristate-13-acetate 18 
showed that the cAMP-PKA signaling pathway positively regulates the AIP promoter. The splice 19 
mutation c.249G>T created an alternative splice-site leading to a frameshift and premature stop-codon. 20 
The c.807C>T mutation leads to decreased mRNA expression both in patient samples and in an in vitro 21 
study.  22 
 23 
Conclusions: The functional characterization of AIP sequence changes is important to identify the 24 
pathogenic role of gene sequence variants. We have shown that exploration of exonic, promoter and 25 
splice-site mutations as well as large deletions result in the putative involvement of AIP in 31% of 26 
families in our FIPA cohort.  27 
 28 
29 
 5
Introduction 1 
 2 
The majority of pituitary adenomas are sporadic, but occasionally they may also occur in a familial 3 
setting (1). In addition to multiple endocrine neoplasia type 1 and Carney complex, familial isolated 4 
pituitary adenoma (FIPA) is an increasingly recognized syndrome. FIPA is an autosomal dominant 5 
disease with low or variable penetrance (2). Germline mutations in the aryl hydrocarbon receptor-6 
interacting protein (AIP) have been identified in 15-40% of FIPA families, most commonly in those with 7 
somatotroph adenomas or with both somatotroph and lactotroph tumors, but rarely in families with other 8 
types of pituitary tumors (3-7). 9 
 AIP appears to function as a tumor suppressor gene: we have previously reported data showing that 10 
mutant AIP proteins lose the ability of wild-type (WT) AIP to decrease cell proliferation and are unable to 11 
bind protein partners (7). Most of the described AIP mutations identified via standard sequencing 12 
techniques change the amino-acid sequence due to missense, nonsense, deletion or insertion mutations. 13 
Other less common mutations that have been identified are those that result in large gene deletions or do 14 
not change the amino-acid sequence, such as promoter mutations or exon/intron junction mutations that 15 
may affect splicing or RNA stability. We have systematically examined our large cohort of patients with 16 
FIPA specifically looking for large deletions, promoter and splice-site mutations in addition to exonic 17 
mutations; we describe 11 new AIP mutation-positive families with 6 novel mutations. We present 18 
functional data on several types of AIP mutations and variants, including, for the first time, on a promoter 19 
mutation, a splice-mutation and a synonymous change which leads to reduced AIP mRNA expression.  20 
21 
 6
Patients and Methods 1 
 2 
FIPA Patients  3 
We studied a cohort of 64 families with FIPA. All patients provided written informed consent and 4 
Institutional Review Board approval was obtained. Genomic DNA was extracted from whole blood using 5 
the QIAmp DNA blood kit (Qiagen, Crawley, UK). Direct sequencing included all the exonic sequences 6 
and exon-intron junctions, and 1200 base-pairs of the promoter region. AIP sequencing data were 7 
compared with a control group of normal Caucasian individuals (n=96) and normal Japanese controls 8 
(n=78), as previously described (7). Multiplex-ligation dependent probe amplification (MLPA) dosage 9 
analysis was carried out to look for partial or whole gene deletions in all the families that tested negative 10 
for germline AIP mutations by direct sequencing and in which a suitable DNA sample was available (17 11 
families were unsuccessfully studied for large gene deletion due to unsuitable DNA samples). MLPA 12 
analysis was carried out according to the manufacturer's instructions, using the P244 MLPA kit (MRC-13 
Holland, Amsterdam, The Netherlands).  14 
 15 
RNA extraction, RT-PCR, cell culture 16 
RNA from whole blood was extracted using Paxgene tube and extraction kit, RNA from GH3 cells was 17 
extracted using the RNeasy Mini Kit (Qiagen). Both protocols include a DNase step. RT-PCR on 1µg 18 
RNA was performed as described previously (7). Real-time PCR was performed using the TaqMan 19 
system (Applied Biosystems (ABI), Warrington, UK). A Custom Taqman Gene Expression Assay AIP 20 
probe-primer surrounding the c.807C>T mutation were designed to quantify the AIP mRNA expression in 21 
both patients and control individuals. Reactions were performed in a triplicate using β-actin as a 22 
housekeeping gene. Data were analyzed using the standard curve method. Rat somatomammotroph GH3 23 
cells were cultured and transfected as previously described (7).  24 
 25 
Promoter mutation 26 
The transcription factor binding-site searching programs TESS (http://www.cbil.upenn.edu/cgi-27 
bin/tess/tess) and Alibaba (http://www.gene-regulation.com/pub/programs/alibaba2/index.html) were 28 
used to identify possible binding site disruption caused by the c.-270_-269AA and c.-220A sequence 29 
changes (7) in the AIP promoter area (Figure 1A&B). A 1.2 kb (upstream from the start codon) PCR 30 
fragment was amplified from gDNA with primers covering the AIP promoter c.-270_-269CG>AA and c.-31 
220G>A mutations. The sequence of the forward primer was 5′TACAACCTCCATCTCCTGGG3′ and 32 
the sequence of the reverse primer was 5′GAGTCCGGAAGTTGCCGAAA3′. The WT fragment was 33 
cloned into the SacI and SpeI sites of the promoterless firefly luciferase vector pGL3 basic (Promega). 34 
 7
Three mutated constructs were prepared from the WT template using the QuikChange site-directed 1 
mutagenesis kit (Stratagene, La Jolla, CA): a dibasic -270_-269AA mutant, a single -220A mutant and a 2 
construct containing both -270_-269AA & -220A mutations (Figure 1C). To study basal and stimulated 3 
activity GH3 cells were transfected with the 4 different constructs and 48h later were treated with db-4 
cAMP (2mM), forskolin (10µM) and phorbol-12-myristate 13-acetate (PMA, 20nM) for 5h. A plasmid 5 
encoding Renilla luciferase, pRL-CMV, (Promega) was included to control for transfection efficiency and 6 
promoter activity was analyzed using the dual luciferase assay (Promega). No blood RNA was available 7 
from these patients. 8 
 9 
Splicing mutation c.249G>T  10 
The ALAMUT program (http://www.interactive-biosoftware.com/alamut/doc/1.5/ 11 
splicing.html) was used to predict whether a novel synonymous sequence variant c.249G>T, G83G 12 
(Family No.28) changes the splicing characteristics of the AIP gene. Primers were designed to detect 13 
possible splice variants (forward 5′GCGGATATCATCGCAAGACT3′, reverse 14 
5′CCTCATCTTCCACATGGAGA3′). RT-PCR using cDNA prepared from blood of an affected family 15 
member was performed as described above. 16 
 17 
Synonymous exonic mutation c.807C>T  18 
The ALAMUT (http://www.interactive-biosoftware.com/alamut/doc/1.5/splicing.html), the ESEfinder 19 
v.3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) and the RESCUE-ESE 20 
(http://genes.mit.edu/burgelab/rescue-ese/) programs were used to predict whether the c.807C>T, F269F 21 
sequence variant of exon 6 we have previously identified (7) changes the splicing characteristics of the 22 
AIP gene (Figure 3A). Conventional and real-time RT-PCRs were performed on patient blood-derived 23 
cDNA using primers spanning the exon 5-6 junction to compare AIP expression between patients 24 
carrying the mutation and control individuals. To construct the minigene gDNA from a patient harboring 25 
the 807C>T mutation was PCR amplified with primers covering part of the exon 5, intron-exon region 26 
and part of exon 6 including the mutation (forward 5′AAGCTGGTGGTCGAGGAGTA3′, reverse 27 
5′CAAAGTGCTGGAGCTGGAC3′). WT and mutant minigene constructs were prepared with the WT 28 
and with the mutant allele. The WT (807C) and mutant (807T) fragments were cloned into the EcoRI site 29 
of pcDNA3.1+ (Invitrogen, Paisley, UK). GH3 cells were transiently transfected for 24-48h with WT and 30 
mutant minigenes separately or together in equal amounts. Expression efficiency was followed by co-31 
 8
transfection of green fluorescent protein at a ratio of 1:10. Expression of the minigene transcripts was 1 
detected using vector-specific primers.  2 
 3 
PDE4A5 interaction 4 
Interactions between AIP and PDE4A5 were performed as described previously (7,8). PDE4A5 was 5 
cloned into the Not I site of pLEXAN to generate a LexA DNA-binding-domain fusion. WT AIP or 3 6 
previously described AIP sequence variants (c.47G>A, R16H (4,9-12); c.145G>A, V49M (5); c.308A>G, 7 
K103R (13)) and a novel stop mutation (c.490C>T, Q164X) were cloned into the Not I site of pGADN to 8 
generate GAL4 activation-domain fusions. All mutations were created by the circular mutagenesis 9 
method and were verified by sequencing prior to use (8). Yeast two-hybrid filter beta-galactosidase assays 10 
were performed in Saccharomyces cerevisiae strain L40. Assay band intensity was quantified by the 11 
Image J software (NIH). 12 
 13 
Statistics 14 
Statistical analysis was performed with StatsDirect software (Buchan I; Addison Wesley Longman, 15 
Cambridge, UK). Data were analyzed with Student t-test and ANOVA, significance was taken at P<0.05. 16 
 17 
 18 
19 
 9
Results 1 
Genetic studies 2 
In our cohort of 64 families (Table 1 and (7)) we identified 20 with heterozygous germline AIP mutations. 3 
We had previously reported 9 of these families (7) and now we report a further 11 AIP mutation families 4 
(Table 1). Of these 11 mutations, 6 have not been previously described.  5 
The novel mutations revealed via sequencing include 2 nonsense mutation (c.622dupC, Glu222X; 6 
c.490C>T, Q164X); a splice-site mutation (c.249G>T, G83G); a complex deletion-insertion mutation 7 
(c.74_81delins7), while 3 families have been found to have the previously well-described c.910C>T, 8 
R304X hotspot (3,4,7,14) mutation and one family the c.911G>A, R304Q hotspot (7) mutation. We also 9 
identified a previously described change (c.896C>T,V299M) in a subject with R304X mutation. 10 
When suitable DNA was available (47 families) we screened our affected patients for large 11 
deletions using MLPA and identified 3 large deletions of the AIP gene in 3 families originally reported 12 
not to harbor an AIP change (7,9). Two of these resulted in the loss of the full length of the AIP gene and 13 
one patient had a previously described exon 2 deletion mutation (15). 14 
In the cohort of 64 families the mean age (± SD) at diagnosis of affected subjects was 34.1±15.6 15 
yr with 24.3±11.5 yr in the AIP mutant families and 41.1±13.3 yr in the AIP negative families (P 16 
<0.00001). Interestingly, 16 of our 20 families with an AIP mutation had at least one member with 17 
gigantism and/or disease onset <18 yr, while only 3 of our 44 families with AIP mutation-negative FIPA 18 
had a member with gigantism and/or disease onset <18 yr. We also observed a difference in the reported 19 
number of affected patients between AIP mutation-positive and negative families, suggesting a difference 20 
in penetrance: the mean number of affected subjects in AIP mutation-positive families was 2.9±1.4yr 21 
while in AIP mutation-negative families it was 2.1±0.4yr (P<0.001). 22 
 23 
AIP promoter mutation causes decreased promoter activity 24 
Two mutations (c.-270_-269CG>AA and c.-220G>A in cis) had previously been identified in a Japanese 25 
FIPA family with 2 sisters suffering from childhood-onset acromegaly and their asymptomatic mother 26 
(7), but not in 96 Caucasian or 78 Japanese normal subjects (Figure 1A&B). The transcription factor 27 
binding site searching programs TESS and Alibaba suggested that the c.-270_-269CG>AA promoter 28 
mutation causes disruption of transcription factor binding sites, such as Sp1 and Oct1. To investigate 29 
whether these sequence changes affected the transcriptional activity of the AIP promoter, we cloned a 1.2 30 
kb upstream fragment of the AIP gene into the pGL3-basic luciferase reporter vector (WT construct). To 31 
identify which of the mutations were functional, 3 mutant constructs were prepared: a promoter construct 32 
with a dibasic change (-270_-269AA), a promoter construct with a single base change (-220A), and a 33 
 10
promoter construct with both changes (-270_-269AA & --220A) (Figure 1C). These were transiently 1 
transfected into GH3 cells and the activity of the promoter was measured using a luciferase assay.  2 
Transfection of the WT promoter and the single -220A promoter construct resulted in an 18-fold 3 
increase of promoter activity compared to empty vector pGL3-basic (Figure 1D). Compared to the WT 4 
promoter construct the dibasic -270_-269AA promoter construct and the double -270_-269AA & -220A 5 
promoter construct showed a significantly decreased promoter activity (P<0.001 and P=0.003, 6 
respectively). These results suggest that the dibasic -270_-269AA promoter mutation, but not the single -7 
220A mutation, causes decreased promoter activity that is likely to have a pathogenic effect in the 8 
patients carrying the dibasic mutation and that the -270_-269 mutation affects binding of transcription 9 
factors(s) important for the activity of the AIP promoter. 10 
 11 
AIP promoter is regulated via the cAMP-PKA signaling pathway  12 
No previous data is available about the regulation of the AIP promoter therefore we treated GH3 cells 13 
transfected with the promoter constructs with db-cAMP (a cAMP analog which activates PKA), forskolin 14 
(an adenylate cyclase activator that activates PKA) and PMA (a protein kinase C activator leading to 15 
activation of the ERK/MAPK pathway) and luciferase activity was measured. Treatment with db-cAMP 16 
and forskolin increased WT promoter activity compared to vehicle (both P<0.05, Figure 1E). Similar 17 
activity was observed with the single -220A promoter construct. However, db-cAMP and forskolin 18 
treatment did not have any effect on the dibasic -270_-269AA mutated promoter and the double 19 
-270_-269AA & -220A mutated promoter. Treatment with PMA did not alter AIP promoter activity in 20 
any of the 4 promoter constructs. These results showed that db-cAMP and forskolin can induce WT 21 
promoter activity, implicating the involvement of the cAMP-PKA signaling pathway in AIP promoter 22 
regulation. These results also suggest that the -270-269 region is required for cAMP-induced AIP 23 
promoter activity.  24 
 25 
Splice mutation c.249G>T causes truncated AIP  26 
A novel mutation (c.249G>T, G83G) was identified in a family (No.28) with 2 childhood-onset pituitary 27 
adenomas (a somatotropinoma and a prolactinoma) and an adult-onset prolactinoma (Figure 2A). The 28 
mutation at the end of exon 2 did not change the amino-acid sequence, but in silico analysis using 29 
ALAMUT predicted that this mutation created a novel 5′ splice site 32 bases upstream from the normal 30 
splice-site resulting in a frameshift and a stop codon after 35 novel amino-acids (Figure 2B). In order to 31 
determine whether this mutation indeed causes alternative splicing , we extracted RNA from blood of one 32 
of the patients. Conventional RT-PCR with primers upstream and downstream of the mutation was 33 
performed and compared to cDNA from a control individual. RT-PCR with the cDNA from the patient 34 
 11
heterozygous for the mutation showed an extra band in addition to the WT band that corresponded to the 1 
size of the predicted alternative product (429bp, Figure 2C). Sequencing of the smaller band confirmed 2 
the identity of the alternatively-spliced transcript. These results confirmed the in silico prediction that the 3 
nucleotide change c.249G>T causes alternative splicing leading to a truncated AIP protein.  4 
 5 
The c.807C>T, F269F mutation results in reduced mRNA expression  6 
A mutation (c.807C>T, F269F) at the beginning of exon 6 had been identified in a family with 2 adult-7 
onset somatotropinomas (7). The mutation did not change the amino-acid sequence, but in silico analysis 8 
(ESEfinder and RESCUE-ESE) suggested loss of a binding site for splice enhancers SRp40 and SRp55 9 
(splicing regulatory proteins that recognize exonic splicing enhancer sequences) in the presence of the 10 
c.807C>T mutation (Figure 3A). Thus, we next explored whether this mutation indeed affected the 11 
splicing of the last AIP exon. cDNA obtained from affected individuals was amplified with different 12 
primer sets covering the exon5-5′UTR region and compared to the WT gene. PCR amplification with the 13 
different primer sets did not show any novel transcripts, but instead patients with the mutation showed 14 
decreased AIP mRNA expression compared to control individuals using both conventional (Figure 3B) 15 
and real-time PCR (Figure 3C). Thus, these data suggests that the c.807C>T mutation may be pathogenic 16 
by causing decreased AIP expression.  17 
To further investigate whether the c.807C>T mutation leads to decreased mRNA expression, we 18 
performed in vitro studies using a minigene construct. The minigene was constructed with an amplified 19 
DNA fragment from a patient carrying the mutation. A WT (807C) and a mutated (807T) minigene 20 
including the 3′ end of exon 5, the intron between exon 5 and 6 and the 5′ end of exon 6 were cloned into 21 
the pcDNA3.1(+) expression vector (Figure 3D). The WT minigene and the mutated minigene were then 22 
transiently transfected into GH3 cells for 48h. To mimic the patients’ heterozygous mutation, cells were 23 
co-transfected with equal amounts of the WT and mutated minigenes. Using conventional (Figure 3E) and 24 
real-time PCR (Figure 3F), we detected decreased amount of the exon5-6 PCR product in the cells 25 
transfected with the mutated minigene (807T) and an intermediate amount with the heterozygous 26 
minigene (co-transfection of WT and mutated minigenes) compared to cells with the WT minigene 27 
construct. These data correspond to the in vivo data that showed decreased AIP mRNA expression in the 28 
patients carrying the c.807C>T heterozygous variant, supporting the pathogenic effect of the mutation.  29 
 30 
The c.896C>T, A299V, a pathogenic variant? 31 
In one of our families (No.10, Table 1), two AIP changes were identified in an asymptomatic male carrier 32 
(65yr). The c.910C>T, R304X (a known pathogenic mutation (7)) and the c.896C>T, A299V (previously 33 
reported in a patient with sporadic acromegaly (9)) changes were found while other family members 34 
 12
showed only one or the other changes. We have cloned this region of the AIP gene from the subject 1 
carrying both mutations and sequenced several colonies. Some of the colonies carried the c.910C>T 2 
change while others the c.896C>T change. These data show that the 2 sequence changes are coded on 2 3 
different chromosomes (in trans) in this patient and suggest that this asymptomatic subject is a compound 4 
heterozygote for these two AIP changes.  5 
 6 
AIP-PDE4A5 interaction  7 
We have studied 4 AIP changes to see if they disrupt the binding of the AIP protein to its partner 8 
PDE4A5 (Figure 4). Our data suggest that while the novel stop mutation c.490C>T, Q164X, and the 9 
previously described c.308A<G, K103R (13) mutation are unable to bind to PDE4A5, the behavior of the 10 
R16H (previously described both in normal and acromegalic subjects (4,9-12)) and V49M (described in a 11 
sporadic childhood-onset acromegaly patient) variants are not different from the WT in terms of PDE4A5 12 
binding in this assay (band intensity (arbitrary units) WT: 99.1, R16H: 92.6, V49M: 96.6, K103R: 53.6, 13 
Q164X: 26.1, Empty vector 45.9). 14 
 15 
Discussion 16 
In our cohort of 64 FIPA families, AIP mutations occurred in 20 families. We have performed genetic and 17 
functional studies to investigate the possible pathogenic role of some of the reported AIP sequence 18 
changes. The main findings of this study are:  19 
1) Six novel AIP germline mutations were identified using sequencing and MLPA; of note is that the 20 
families with mutations identified with MLPA were previously reported to be negative for AIP 21 
mutations (7).  22 
2) The cAMP-PKA signaling pathway positively regulates the activity of the AIP promoter. The promoter 23 
mutation we characterized had a decreased promoter activity compared to WT promoter.  24 
3) The exonic synonymous mutations we studied caused abnormal splicing and decreased AIP mRNA 25 
expression.  26 
4) AIP changes identified in pituitary adenoma patients may represent rare single nucleotide 27 
polymorphisms, and thus functional analysis of the various AIP sequence alterations is vital to 28 
demonstrate the involvement of AIP in the disease process.  29 
 30 
We used the MLPA technique to identify large gene deletions in our families previously shown to 31 
be negative for AIP mutations using sequencing. Out of the 47 families where a suitable sample was 32 
available, 3 families (6.4%) showed a large gene deletion. This suggests that MLPA or other techniques 33 
suitable to detect large deletions should be part of the DNA analysis of patients with FIPA. 34 
 13
To date, there are no published data on AIP promoter regulation. The finding of the promoter 1 
mutation led us to investigate possible mechanisms that could regulate the AIP promoter. Our data 2 
suggest that the presence of the dibasic c.-270_-269CG>AA mutation, but not the c.-220G>A mutation, 3 
reduces basal promoter activity leading to decreased AIP gene expression. As patients with AIP mutations 4 
often have somatotroph adenomas, and the cAMP-PKA pathway is known to be important in this cell 5 
type, we performed studies using activators of this pathway. GH3 cells transfected with the AIP promoter 6 
constructs were treated with db-cAMP, forskolin as well as a PKC pathway stimulator PMA. PKA-7 
pathway activation resulted in stimulation of the promoter activity of the WT promoter construct whereas 8 
in the dibasic mutated construct (-270_-269CG>AA) no effect was observed. The treatment with PMA 9 
did not have any effect on the AIP promoter. Once again, these data suggest that the -270-269 region is 10 
involved in the promoter regulation and that it is necessary for cAMP-PKA signaling induction of the AIP 11 
promoter. Based on prediction programs the mutation at -270-269 position would disrupt Sp1- or Oct1-12 
binding sites. Sp1 belongs to the zinc-finger transcription factor proteins, while Oct1 is a member of the 13 
POU homeodomain transcription factor family. Among other effects both these factors have been 14 
suggested to play a role in cell proliferation and tumorigenesis and further studies are needed to 15 
investigate whether Sp1 or Oct1 truly regulate the AIP promoter.  16 
As predicted in silico, the c.249G>T, G83G mutation, found in a family with two childhood-onset 17 
and one adult-onset pituitary adenoma, causes an alternative AIP splice transcript which leads to a 18 
truncated protein due to the loss of 33 base-pairs resulting in a frameshift including 35 novel amino-acids 19 
followed by an early termination codon. This strongly suggests that this mutation is pathogenic.  20 
The c.807C>T, F269F mutation located at the beginning of exon 6, identified in a family with 2 21 
adult-onset cases of acromegaly, leads to decreased AIP mRNA expression in a patient and an 22 
asymptomatic carrier. Our search for alternative splice products using various sets of oligonucleotides did 23 
not reveal an alternative splice-product. Therefore we further investigated this mutation by using the 24 
minigene approach. GH3 cells transiently transfected with WT and mutated minigene constructs or with a 25 
mixture of the two constructs confirmed decreased presence of the exon5-6 region of the gene in the 26 
presence of the mutated nucleotide. A prediction program revealed that this mutation could disrupt the 27 
binding of the splicing regulatory proteins Sp40 and Sp55 which would lead to a less favorable splice-28 
acceptor site and consequently the loss of exon 6. It is well-known that the C-terminal end of the AIP 29 
molecule is crucial for its activity so the loss of this last exon would lead to a dysfunctional protein. 30 
Another possible mechanism would be the destabilization of the mRNA leading to reduced mRNA levels 31 
which we demonstrated both in the patients as well as in the minigene construct. 32 
We identified an asymptomatic carrier subject with two changes in the AIP gene and showed that 33 
they are located on opposite parental chromosomes. It has previously been demonstrated that the R304X 34 
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mutation disrupts the function of the AIP molecule and this mutation has been described in numerous 1 
FIPA families. The A299V, c.896C>T change involves a conservative amino-acid substitution of alanine 2 
to valine and this amino-acid is not part of the tetratricopeptide repeat (TPR) domain consensus residues 3 
(16). It has been previously identified in a sporadic patient with acromegaly (9) and family members of 4 
this patient carrying only the A299V variant are all asymptomatic. If this change is a pathogenic change, 5 
our subject would be a compound heterozygote for AIP mutations. As AIP knockout mice are not viable, 6 
(they die at embryonic age due to cardiac malformations (17)), while our patient is currently 65yr old and 7 
asymptomatic, we suggest that the A299V change might not be a pathogenic variant, although further 8 
studies are needed to confirm this.  9 
The AIP molecule harbors three TPR domains. Crystal structure studies demonstrated that the 10 
overall architecture of the TPR domains and certain amino-acids within are well-conserved (16). Two 11 
previously described missense AIP mutations affect these conserved TPR domain amino-acids, the 12 
C238Y (7) and the K241E (4), while the A299V do not affect these important residues.  13 
Protein-protein interaction studies including WT AIP and mutant AIP (including mutations 14 
detected in our patients) revealed loss of interaction between some mutants and the AIP interacting 15 
partner PDE4A5 (8). We have previously shown that this interaction is lost in the presence of pathogenic 16 
AIP mutations (7). We have now carried out this assessment on recently-described AIP changes and 17 
found that a stop mutation identified in our cohort, and a missense mutation identified in a pediatric 18 
pituitary adenoma case (13) disrupts the binding of the AIP molecule to PDE4A5. However, the R16H 19 
change which has been previously described in several normal subjects as well as in patients showed no 20 
PDE4A5 binding. Interestingly, the V49M change, which has been described in a sporadic childhood-21 
onset acromegaly patient from Japan (5) and was not found in 191 Japanese controls or in any of the 22 
published Caucasian control data, also showed normal PDE4A5 binding. Clearly further studies are 23 
needed to clarify whether the lack of AIP-PDE4A5 interaction is important for the pituitary pathogenic 24 
process.  25 
In summary, functional characterization of novel and previously described AIP germline 26 
mutations revealed that a promoter mutation causes a decreased promoter activity and that the AIP 27 
promoter is positively regulated by the cAMP-PKA pathway. A splice mutation leads to abnormal AIP 28 
mRNA and a truncated transcript, while a synonymous change reduces the expression of the AIP mRNA. 29 
suggesting that these mutations are likely to be pathogenic. Searching for large deletions using MLPA 30 
and functional characterization of rare AIP changes helps to clarify the pathogenic role of AIP in patients 31 
with familial and sporadic pituitary adenomas, whilst increasing the proportion of patients with FIPA in 32 
whom AIP is likely involved as a causative factor.  33 
 34 
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Table 1. Clinical and genetic data of families with familial isolated pituitary adenoma  
 
Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
1 (F3) UK Prolactinoma Male 43 Macroadenoma No mutation Not done 
Prolactinoma Male 17 Microadenoma 
Prolactinoma Female 23 Microadenoma 
2 (F17) UK NFPA Male 60 Macroadenoma No mutation No mutation 
NFPA Female 64 Macroadenoma 
3 (F24) Brazil Cushing’s 
disease 
Female 21 Macroadenoma No mutation Not done 
Prolactinoma Female 34 Macroadenoma 
4 (F25) Brazil Prolactinoma Male 51 Microadenoma No mutation No mutation 
Prolactinoma Male 47 Macroadenoma 
Prolactinoma Female 35 Microadenoma 
5 (F29)  UK Acromegaly Male 24 Macroadenoma Glu222X (c.622dupC)  No mutation 
Acromegaly Male 28 Macroadenoma 
6 (F31) Hungary Prolactinoma Male 51 Macroadenoma No mutation Not done 
Prolactinoma Male .46 Macroadenoma 
7 (F32) Germany Gigantism Female 23 Macroadenoma Q164X (490c>T) No mutation 
Gigantism Male 20 Macroadenoma 
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Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
8 (F33) USA Acromegaly Female 57 Macroadenoma No mutation Not done 
NFPA Male 47 Macroadenoma 
9 (F34)* UK NFPA female 17 Microadenoma No mutation Ex1_Ex2del  
(c.1104-1109_279+578)  Prolactinoma, 
subclinical 
acromegaly 
female 29 2 microadenomas 
NFPA Male 18 Macroadenoma 
Gigantism Male 18 Macroadenoma 
10 (F35) Ireland Acromegaly Male 20 Macroadenoma R304X No mutation 
Gigantism Male 16 Macroadenoma 
Prolactinoma Female 30 Microadenoma 
11 (F36) Sweden Acromegaly Female 31 Macroadenoma No mutation No mutation 
Acromegaly Male N/A N/A 
12 (F37) USA Acromegaly Male 52 Microadenoma No mutation No mutation 
NFPA Male 43 Microadenoma 
13 (F38) Serbia NFPA Female 36 Microadenoma No mutation Not done 
Prolactinoma Female 25 Microadenoma 
14 (F40) UK Acromegaly Female 59 Microadenoma No mutation No mutation 
Prolactinoma Female 28 Microadenoma 
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Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
Prolactinoma Female 38 Microadenoma 
15 (F41) Japan Acromegaly Male 59 Macroadenoma No mutation No mutation 
  Acromegaly Female 30 N/A 
16 (F42) Serbia NFPA Female 73 Macroadenoma No mutation Not done 
NFPA Male 40 Macroadenoma 
17 (F43)* Australia Gigantism Male 13 Microadenoma c.74_81delins7/N No mutation 
Acromegaly 
& 
prolactinoma 
Male 38 Macroadenoma 
Prolactinoma Female 25 Macroadenoma 
Acromegaly Male 27 Macroadenoma 
Acromegaly Female 32 Macroadenoma 
18 (F44) USA NFPA Female 52 Macroadenoma R304Q No mutation 
Prolactinoma Female 23 Macroadenoma 
19 (F45) Brazil NFPA Male 54 Macroadenoma No mutation No mutation 
  NFPA Male 44 Macroadenoma 
20 (F46) Brazil NFPA Female 28 Macroadenoma No mutation No mutation 
  NFPA Male N/A Macroadenoma 
21 (F47) Greece Acromegaly Female 42 Macroadenoma No mutation No mutation 
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Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
Acromegaly Female 40 Macroadenoma 
22 (F49) UK Acromegaly Female 36 Macroadenoma No mutation No mutation 
Acromegaly Female N/A N/A 
23 (F50) Serbia Prolactinoma Male 40 Macroadenoma No mutation No mutation 
Prolactinoma Female N/A Microadenoma 
24 (F51) Ireland Acromegaly Male N/A Macroadenoma No mutation No mutation 
Acromegaly Male N/A N/A 
25 (F53) UK Acromegaly Female 50 Macroadenoma No mutation No mutation 
Acromegaly Female N/A N/A 
Gigantism Male N/A N/A 
26 (F54) Germany Acromegaly Male N/A Macroadenoma No mutation No mutation 
Acromegaly Male N/A N/A 
27 (F55) UK Prolactinoma Female 26 Microadenoma No mutation Not done 
Acromegaly Female 46 Macroadenoma 
28 (F56) UK Prolactinoma Male 14 Macroadenoma G83G c.249G>T No mutation 
Prolactinoma Male 60 Macroadenoma 
Gigantism Male N/A N/A 
29 (F58) Turkey Acromegaly Female 31  Macroadenoma No mutation No mutation 
Gigantism Male 18 Macroadenoma 
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Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
30 (F59) UK Gigantism Female 6 Macroadenoma R304X No mutation 
Acromegaly Female 32 Macroadenoma 
Acromegaly Male 17 Macroadenoma 
Prolactinoma Male N/A Macroadenoma 
Prolactinoma Female 16 Macroadenoma 
31 (F60) UK Acromegaly Female 17 Macroadenoma No mutation No mutation 
Prolactinoma Female 38 Microadenoma 
32 (F61) UK Acromegaly Female 23 Macroadenoma No mutation No mutation 
Prolactinoma Female 25 Macroadenoma 
33 (F62) UK Acromegaly Female 25 Macroadenoma No mutation No mutation 
Acromegaly Male 51 Macroadenoma 
34 (F64) UK Prolactinoma Female 23 Microadenoma No mutation Not done 
Prolactinoma Female 30 Macroadenoma 
35 (F65) UK NFPA Male 60 Macroadenoma No mutation No mutation 
NFPA Male 65 Macroadenoma 
36 (F67) Russia Prolactinoma Female 44 Microadenoma No mutation Not done 
Prolactinoma Female 12 Macroadenoma 
37 (F68) USA Acromegaly Male 70 Macroadenoma No mutation Not done 
Acromegaly Female 24 Macroadenoma 
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Family ID Country 
of origin 
Clinical 
diagnosis 
Sex  Age(yr) at  
diagnosis 
Size of pituitary 
adenoma 
Germline promoter, exon and 
exon-intron junction sequencing 
MLPA 
38 (F70) Ireland Gigantism Male 19 Macroadenoma R304X No mutation 
Gigantism Female 13 Macroadenoma 
Previously we reported to be negative for AIP mutation 
39 (Family C)* Serbia Gigantism Male 20 Macroadenoma No mutation Exon1-6 deletion 
 Gigantism Female 10 Macroadenoma 
40 (F19)* UK Acromegaly Male 35 Macroadenoma No mutation Exon1-6 deletion 
(c.1-?_993+?del) Gigantism Male 19 Macroadenoma 
Acromegaly Male 23 Macroadenoma 
*The family has been previously reported: 9 (9,15), 17 (18), 39 (7,19), 40 (7) 
 
 22
 
 
 
Reference List 
 
 1.  Melmed S 2006 Medical progress: Acromegaly. N Engl J Med 355:2558-2573. 
 2.  Beckers A, Daly AF 2007 The clinical, pathological, and genetic features of familial isolated 
pituitary adenomas. Eur J Endocrinol 157:371-382. 
 3.  Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, 
Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De ME, Makinen MJ, Launonen V, 
Karhu A, Aaltonen LA 2006 Pituitary adenoma predisposition caused by germline mutations 
in the AIP gene. Science 312:1228-1230. 
 4.  Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, 
Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De 
Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate 
MI, Bertagna X, Garcia BN, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, 
Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, 
Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, 
Brue T, Bours V, Teh BT, Beckers A 2007 Aryl hydrocarbon receptor-interacting protein 
gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin 
Endocrinol Metab 92:1891-1896. 
 5.  Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K 2007 The aryl 
hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting 
adenomas. Clin Endocrinol (Oxf) 66:499-502. 
 6.  Toledo RA, Lourenco DM, Jr., Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses 
CB, Toledo SP, Dahia PL 2007 Germline mutation in the aryl hydrocarbon receptor 
interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 92:1934-1937. 
 7.  Leontiou CA, Gueorguiev M, van der SJ, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja 
SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, 
Wass JA, Popovic V, Ribeiro-Oliveira A, Jr., Gadelha MR, Monson JP, Akker SA, Davis 
JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, 
Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M 2008 The 
role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 
93:2390-2401. 
 8.  Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, 
Baillie GS, Houslay MD 2003 Attenuation of the activity of the cAMP-specific 
phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 
278:33351-33363. 
 9.  Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O, Paschke R, 
Saeger W, van der Luijt RB, Sane T, Robledo M, De ME, Weil RJ, Wasik A, Zielinski G, 
Lucewicz O, Lubinski J, Launonen V, Vahteristo P, Aaltonen LA 2007 Molecular diagnosis 
of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein 
gene mutations. Proc Natl Acad Sci USA 104:4101-4105. 
 10.  Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P, Schilling T 2008 Aryl 
hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone 
secreting or non-secreting pituitary adenomas. Exp Clin Endorcrinol Diabetes 116:625-628. 
 23
 11.  Yaneva M, Daly AF, Tichomirowa MA, Vanbellinghen JF, Hagelstein MT, Bours V, 
Zacharieva S, Beckers A 2008 Aryl hydrocarbon receptor interacting protein gene mutations 
in bulgarian FIPA and young sporadic pituitary adenoma patients. Proc of the 90th Annual 
Meet of the Endocrine Soc P3-520: 
 12.  Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, 
Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson 
ML 2007 Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein 
gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients 
with macroadenomas. Eur J Endocrinol 157:1-8. 
 13.  Beckers A, Vanbellinghen JF, Boikos S, Martari M, Verma S, Daly AF, Raygada M, Keil 
M, Papademetriou J, Drori-Herishanu L, Horvath A, Nesterova M, Tichomirowa MA, 
Bours V, Marx S, Agarwal SK, Salvatori R, Stratakis CA 2008 Germline AIP, MEN1, 
PRKAR1A, CDKN1B (p27Kip1) and CDKN2C (p18INK4c) gene mutations in a large cohort of 
pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic 
features. Proc of the 90th Annual Meet of the Endocrine Soc OR38-1: 
 14.  Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, 
D'Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, 
Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, 
Cantore G, Alesse E, Beckers A 2009 Expression of aryl hydrocarbon receptor (AHR) and 
AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr 
Relat Cancer 16:1029-1043. 
 15.  Georgitsi M, Heliovaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O, Salmela 
P, Sane T, De ME, Cannavo S, Gundogdu S, Lucassen A, Izatt L, Aylwin S, Bano G, 
Hodgson S, Koch CA, Karhu A, Aaltonen LA 2008 Large genomic deletions of aryl 
hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition. J Clin 
Endocrinol Metab 93:4146-4151. 
 16.  Hidalgo-de-Quintana J, Evans RJ, Cheetham ME, van der Spuy J 2008 The Leber 
congenital amaurosis protein AIPL1 functions as part of a chaperone heterocomplex. Invest 
Ophthalmol Vis Sci 49:2878-2887. 
 17.  Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA 2007 Deletion of the aryl 
hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic 
lethality. J Biol Chem 282:35924-35932. 
 18.  Pestell RG, Alford FP, Best JD 1989 Familial acromegaly. Acta Endocrinol (Copenh) 
121:286-289. 
 19.  Soares BS, Eguchi K, Frohman LA 2005 Tumor deletion mapping on chromosome 11q13 in 
eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J 
Clin Endocrinol Metab 90:6580-6587. 
 
 
